Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer
- PMID: 23083868
- DOI: 10.1016/j.juro.2012.08.029
Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer
Abstract
Purpose: We investigated the effects of cigarette smoking status, cumulative exposure and time from cessation on disease recurrence and progression in patients with a history of recurrent nonmuscle invasive bladder cancer.
Materials and methods: A total of 390 patients with recurrent nonmuscle invasive bladder cancer were treated with transurethral resection of the bladder, of whom 159 (41%) received instillation therapy immediately postoperatively and 73 (19%) received adjuvant intravesical immunotherapy or chemotherapy. Smoking history included smoking status, number of cigarettes per day, smoking duration in years and years since smoking cessation. Cumulative smoking exposure was categorized as light short-term--19 or fewer cigarettes per day and 19.9 years or less, moderate--all combinations except light short-term and heavy long-term, and heavy long-term--20 or greater cigarettes per day and 20 years or greater.
Results: A total of 91 (23%), 192 (49%) and 107 patients (28%) were never, former and current smokers, respectively. Of ever smokers 56 (19%), 156 (52%) and 87 (29%) were light short-term, moderate and heavy long-term smokers, respectively. There was no difference in the risk of disease recurrence and progression among current, former and never smokers. On univariable analyses in ever smokers the risk of disease recurrence and progression increased with augmented smoking intensity (p ≤ 0.015), duration (p <0.001) and cumulative exposure (p <0.001). On multivariable analyses cumulative smoking exposure was an independent risk factor for disease recurrence and progression (p ≤ 0.003). Smoking cessation greater than 10 years before treatment was independently associated with decreased disease recurrence compared to current smoking (HR 0.4, p <0.001). In addition, current smokers had worse survival than former smokers, who in turn had worse survival than never smokers (p >0.05).
Conclusions: There is a dose-response relationship of smoking exposure and smoking cessation with disease recurrence and progression in ever smokers with a history of recurrent nonmuscle invasive bladder cancer. These findings support counseling on smoking cessation benefits.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.J Urol. 2012 Dec;188(6):2127-8. doi: 10.1016/j.juro.2012.08.250. Epub 2012 Oct 18. J Urol. 2012. PMID: 23083848 No abstract available.
Similar articles
-
Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.Eur Urol. 2013 Sep;64(3):456-64. doi: 10.1016/j.eururo.2012.11.039. Epub 2012 Nov 27. Eur Urol. 2013. PMID: 23206854
-
Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes.BJU Int. 2013 Sep;112(5):623-37. doi: 10.1111/bju.12014. Epub 2013 Mar 6. BJU Int. 2013. PMID: 23465088
-
Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.Urology. 2013 Feb;81(2):277-81. doi: 10.1016/j.urology.2012.09.040. Urology. 2013. PMID: 23374781
-
Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer.Curr Opin Urol. 2014 Sep;24(5):492-9. doi: 10.1097/MOU.0000000000000079. Curr Opin Urol. 2014. PMID: 24887046 Review.
-
Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.Curr Opin Urol. 2007 Sep;17(5):352-7. doi: 10.1097/MOU.0b013e3281c55f2b. Curr Opin Urol. 2007. PMID: 17762630 Review.
Cited by
-
Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.Rambam Maimonides Med J. 2017 Oct 16;8(4):e0040. doi: 10.5041/RMMJ.10314. Rambam Maimonides Med J. 2017. PMID: 28872454 Free PMC article. Review.
-
The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis.J Cancer Res Clin Oncol. 2023 Jun;149(6):2673-2691. doi: 10.1007/s00432-022-04464-6. Epub 2022 Nov 21. J Cancer Res Clin Oncol. 2023. PMID: 36404390 Free PMC article.
-
Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer.World J Urol. 2017 Feb;35(2):229-235. doi: 10.1007/s00345-016-1852-0. Epub 2016 Jun 6. World J Urol. 2017. PMID: 27272203
-
Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.Bladder Cancer. 2020;6(1):9-23. doi: 10.3233/blc-190249. Epub 2020 Mar 28. Bladder Cancer. 2020. PMID: 34095407 Free PMC article.
-
Smoking-related genitourinary cancers: A global call to action in smoking cessation.Rev Urol. 2016;18(4):194-204. doi: 10.3909/riu0729. Rev Urol. 2016. PMID: 28127261 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical